Will Snowflake Reach $300 This Year?
Snowflake (NYSE:SNOW | SNOW Price Prediction) has been one of 2026’s most violent round trips, plunging to $144.48 in April before ripping back above $230. The question on every shareholder’s mind is whether the…
The Full Ledger
Latest
Every story as it publishes, newest first.
The Portfolio That Quietly Pays For Two Cruises Every Year
Most retirees treat cruise fares like an occasional splurge funded from cash on hand or a withdrawal from the portfolio. There is another way to frame the same expense: build an income stream that…
FuelCell Energy Is Up 14% Today: Is It Outperforming Other Fuel Cell Stocks Like Plug Power and Bloom Energy?
FuelCell Energy‘s (NASDAQ:FCEL) stock is up 14% to $24.91 in Wednesday morning trading, decisively outpacing other major fuel-cell names. The catalyst is company-specific: FuelCell Energy and Fit Energy USA LP announced a strategic agreement…
The 2 Signals That Will Determine IBIT’s Next 12 Months
The iShares Bitcoin Trust ETF (NASDAQ:IBIT) is having its first real bear market as a public fund. IBIT closed near $36 on June 18, down roughly 28% year to date and about 40% over…
Live Nasdaq Composite: Tech Stages a Comeback as Memory Chip Stocks Lead the Rebound
Live Updates Markets Lose Steam1:53pm ETThe markets have run out of steam ahead of Micron’s earnings after the bell. After leading the market higher earlier today with a 4% gain, MU stock has reversed…
“I Was Really Hoping Not to Have to Work That Long.” A Late-Start Saver Confronts the Age 73 RMD Reality on The Ramsey Show
On the April 22, 2026 episode of The Ramsey Show titled “Stop Living Paycheck to Paycheck, Start Living With Options”, a caller laid out a fear many late starters share but rarely voice: “I…
Stanley Druckenmiller Backs These 3 AI Infrastructure Stocks: Should You Follow?
Billionaire investor Stanley Druckenmiller has filed positions in three AI infrastructure semiconductor stocks, but the real question is whether the valuations still make sense after one of them surged over 600% in a single…
Is “VOO And Chill” Actually A Good Way to Invest?
The Vanguard S&P 500 ETF (VOO) is the largest ETF on the U.S. market, with just over $1 trillion in assets under management. It got there because of several compounding factors: the strong performance…
Your Part D Drug Plan Costs $0. Medicare Still Bills You Up to $91 a Month for It
A 67-year-old retiree shops for Part D coverage during open enrollment and finds a $0-premium drug plan available in her ZIP code. It looks like an easy decision. Then January arrives, and her Social…
Stock Market Live June 24, 2026: S&P 500 (SPY) Attempting to Regain Momentum
Live Updates Micron Earnings Could Be the Next Big Test for AI8:59am ETInvestors have spent much of this year riding a monster wave of AI momentum. Now, as all eyes turn to memory-chip maker…
Yesterday’s Tech Rout Shows How Leveraged ETFs Can Destroy Wealth
The stock market has rewarded risk-taking for much of the past three years. Artificial intelligence spending continues to fuel demand for technology stocks, semiconductor companies have generated outsized gains, and investors have increasingly looked…
The Beaten-Down Stock Wall Street Insiders Are Quietly Loading Up On
Two company directors spent millions buying their own stock in the days after a brutal earnings miss, right near 52-week lows, while every analyst covering the name holds a price target far above where…
5 High-Yielding S&P 500 Stocks Trading at Double-Digit Discounts Are Incredible Strong Buys Now
The Standard & Poor’s 500 is a stock market index that tracks the performance of the 500 biggest companies in the United States. It is considered a top indicator of the U.S. stock market’s…
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
Pre-Market Stock Futures: Futures are trading higher this morning, but if you’ve ever heard the old saying, “when the chips are down”, that was the poster child phrase for Tuesday’s session, as technology…
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in…